NCT02384395View on ClinicalTrials.gov

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 6, 2020

Study Completion Date

September 17, 2021

Conditions
HIVAcute HIV Infection
Interventions
DRUG

Dolutegravir 50 mg

Initial therapy for AHI

DRUG

Lamivudine 300 mg

Initial therapy for AHI

DRUG

Abacavir 600 mg

Initial therapy for AHI

Trial Locations (2)

27599

University of North Carolina, Chapel Hill

27710

Duke University Health System, Durham

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER